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Tracking plasma DNA mutation dynamics in estrogen
receptor positive metastatic breast cancer with dPCR-SEQ
Sunil Kumar 1,2, Daniel Lindsay2, Q. Brent Chen 1, Amy L. Garrett1, Xianming M. Tan1,3, Carey K. Anders1,4, Lisa A. Carey1,4 and
Gaorav P. Gupta 1,2
Serial monitoring of plasma DNA mutations in estrogen receptor positive metastatic breast cancer (ER+MBC) holds promise as an
early predictor of therapeutic response. Here, we developed dPCR-SEQ, a customized assay that utilizes digital PCR-based target
enrichment followed by next-generation sequencing to analyze plasma DNA mutations in ESR1, PIK3CA, and TP53. We validated
dPCR-SEQ in a prospective cohort of 58 patients with ER+MBC and demonstrate excellent concordance with hotspot ESR1
mutation abundance measured by conventional digital PCR. The dPCR-SEQ assay revealed ESR1, PIK3CA, and TP53 plasma ctDNA
mutations in 55%, 32%, and 32% of the study patients, respectively. We also observed dynamic changes in ESR1, PIK3CA, and TP53
ctDNA mutant allele fraction (MAF) that were frequently discordant between the different genes. Thus, monitoring plasma DNA
mutation dynamics using a dPCR-SEQ assay is feasible, accurate, and may be investigated as a biomarker of therapeutic response in
ER+MBC.
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INTRODUCTION
The detection and monitoring of circulating tumor DNA (ctDNA)
mutations in ER+MBC patients has emerged as a promising
predictive biomarker of therapeutic sensitivity.1–6 Digital PCR
(dPCR) is an established and cost-effective technology to serially
monitor plasma DNA mutation kinetics with exceptional accuracy,
sensitivity, and specificity.7 However, dPCR is limited to detecting
a relatively small number of hotspot target alleles for which
primers and/or probes are specifically designed, and is not well
suited for the analysis of genes (e.g., TP53) where pathogenic
mutations are heterogeneous. In contrast, plasma ctDNA NGS-
based assays have the potential to identify a broader genomic
target region, yet concerns have arisen regarding their sensitivity,
specificity, and accuracy of measuring mutant allele fraction (MAF)
of target alleles in plasma ctDNA.8 Furthermore, the high cost and
complexity of bioinformatics analysis of advanced NGS-based
assays9 are barriers for implementing serial NGS-based assessment
of patients over time.
RESULTS
Design and implementation of dPCR-SEQ
Here we report the development of dPCR-SEQ, which utilizes
digital PCR technology for target enrichment followed by next-
generation sequencing (Fig. 1a, Supplementary Methods). We
designed a custom primer set for use in the Raindance
Thunderbolts OpenSource platform to perform multiplexed
amplification of ESR1 and TP53 coding regions and hotspot
mutation regions in PIK3CA, PIK3R1, and POLE (Supplementary
Table 1). Only mutations in ESR1, PIK3CA, and TP53 were
recurrently observed in our patient cohort; thus, the analyses
presented here are limited to the amplicons targeting these genes
in the dPCR-SEQ panel. The amplicons were limited to <120 bp
due to the high fragmentation of plasma ctDNA. Up to 16 samples
were multiplexed on a MiSeq 2 × 150 bp v3 chip, to achieve mean
read depth >3000× (Supplementary Fig. S1a). The FASTQ files
were de-multiplexed and aligned to the human reference genome
for variant analysis (detailed methods provided in Supplementary
Information). The MAF was calculated as the percentage of variant
alleles relative to the total sequenced alleles for each position in
the target gene coding sequence. A MAF threshold of 1.6% was
adequate to eliminate false positive mutations in control genomic
DNA when the input material was at least 10 ng (Supplementary
Fig. S1b). The streamlined workflow for dPCR-SEQ assay is simple,
fast, and cost-effective, with an estimated per sample reagent and
sequencing cost of ~$300, and analyzed results available in as few
as 3 days.
Detection of hotspot ESR1 mutations by dPCR
Our goal was to evaluate the feasibility and performance of dPCR-
SEQ on a clinical cohort of plasma ctDNA specimens. Towards this
goal, we conducted a prospective biomarker study of 58 patients
with ER+MBC who had progressed on at least one prior line of
endocrine therapy. The prior and current treatment exposures for
these patients were heterogeneous, and are described in
Supplementary Table S2. In some cases, followup blood samples
were obtained while they underwent systemic therapy, typically
4–6 weeks after the first blood sample. The baseline blood
samples were analyzed with a multiplexed dPCR assay validated
for ultra-sensitive detection of WT and hotspot ESR1 mutations
(D538G, Y537S, Y537C, and Y537N, Supplementary Fig. S2a-d). A
plasma ctDNA hotspot ESR1 mutation was identified in 16/58
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patients (28%) (Supplementary Fig. 3a). The hotspot ESR1MAF was
calculated as the percentage of mutant allele relative to the sum
of mutant and wild-type alleles detected by dPCR. As expected,
the presence of a hotspot ESR1 mutation in baseline plasma
ctDNA correlated with shorter progression-free survival (PFS)
(Supplementary Fig. 3b). However, we did not observe a
correlation between a reduction in mutation abundance and
prolonged PFS (Supplementary Fig. 4a-b) in a limited subset of 11
ESR1 mutation positive patients with followup blood samples
available for analysis. Together with another recent report,5 these
findings suggest that ESR1 mutations are frequently subclonal and
their dynamics may not reflect the entirety of disease response.
Comparison of dPCR-SEQ and dPCR in clinical samples
We were able to perform dPCR-SEQ on 31 out of 58 patients (58%)
in our cohort due to a recommended assay input of 10 ng plasma
DNA. Our study collected 6–8ml of blood at each timepoint, and it
is likely that doubling the volume of blood collected would have
substantially increased the proportion of analyzable samples.
Mutations in ESR1, PIK3CA, and/or TP53 were identified by dPCR-
SEQ in 23/31 patients (74%, Fig. 1b). As expected, the most
common ESR1 mutations identified were D538G and Y537S,
although we also observed non-hotspot ESR1 mutations scattered
across the ESR coding region in 35% of the patient cohort
(Supplementary Fig. 5). A similarly high prevalence of non-hotspot
ESR1 mutations were identified in a recent plasma ctDNA NGS
study of ER+MBC, whereas they were not identified in ER
negative cancer patients.10 Further research is necessary to
determine if these non-canonical ESR1 mutations observed in
plasma ctDNA are indeed tumor-derived and if they have any
impact on therapeutic sensitivity. Consistent with expected
results, all of the PIK3CA mutations identified were oncogenic
hotspot mutations, whereas mutations in the tumor suppressor
TP53 were scattered across the coding sequence and infrequently
recurrent (Supplementary Fig. 5).
Hotspot ESR1 mutations were identified in 11 out of 31 patients
(35%, Fig. 1c), and there was exceptional concordance between
the ESR1 MAF as measured by dPCR-SEQ and by conventional
dPCR (Fig. 1d, R2= 0.96). Three out of 31 patients had a hotspot
ESR1 mutation detected by dPCR at an abundance that was below
the 1.6% detection threshold for dPCR-SEQ. Based on this analysis
of hotspot ESR1 mutations, we estimate that dPCR-SEQ has 79%
sensitivity (11/14) and 100% specificity (17/17). Given the
increased sensitivity of dPCR relative to dPCR-SEQ, we performed
a combined analysis of all 58 patients in our cohort. Patients who
had a baseline ctDNA mutation in ESR1, PIK3CA, and/or TP53
detected by either assay had significantly worse PFS relative to the
remainder of patients in our cohort (Fig. 2a, HR 3.8, 95% CI
1.9–7.6).
Mutation dynamics in patients undergoing systemic therapy
We were also able to perform dPCR-SEQ at two or more
timepoints in seven patients. Matched analyses by dPCR-SEQ in
the same patient revealed marked changes in the MAF for ESR1,
PIK3CA, and TP53 at different timepoints during treatment with
systemic therapy (Fig. 2b, c). In three patients (209, 235, and 238),
the cumulative MAF decreased at the followup timepoint. Among
the four patients who had an increase in cumulative MAF, there
were frequently discordant effects among the different mutant
alleles, indicating high levels of mutational heterogeneity (Fig. 2c).
DISCUSSION
Collectively, these findings demonstrate the feasibility and
favorable performance profile of a streamlined and cost-effective
plasma ctDNA NGS assay that utilizes digital PCR for target
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Fig. 1 Detection of ESR1, PIK3CA, and TP53 mutations in plasma ctDNA from ER+MBC patients. a Schematic of the dPCR-SEQ workflow for
plasma ctDNA analysis. b Summary of plasma ctDNA mutations identified in 31 patients analyzed for the presence of ESR1, PIK3CA, and TP53
mutations by dPCR-SEQ. ESR1 mutations are sub-classified as hotspot or non-hotspot. Some patients had both hotspot and non-hotspot
mutations (shown in the shades of red and blue). PIK3CA and TP53 mutations were frequently observed and were consistent with known
pathogenic mutations. c Mutant allele frequency and identity of ESR1 coding sequence mutations identified by dPCR-SEQ in patients who
were positive by the dPCR ESR1 hotspot mutation assay. d Linear regression analysis of ESR1 hotspot mutation frequency calculated by dPCR
and dPCR-SEQ
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enrichment of ESR1, PIK3CA, and TP53 coding regions. Our
preliminary findings in a cohort of ER+MBC patients suggest
that ctDNA mutation dynamics vary significantly between patients
and at different timepoints during therapy. Future studies will be
necessary to evaluate whether serial monitoring of plasma DNA
mutation dynamics using both dPCR and/or NGS may facilitate
early detection of therapeutic response in ER+MBC.
METHODS
Chemicals and reagents
2x TaqMan® Genotyping Master Mix was purchased from Applied
Biosystems (Foster City, CA). 125 bp genomic fragments for the ESR1 wild
type locus and the four most common hotspot mutations (p.D538G, p.
Y537G, p.Y537S, and p.Y537N) were synthesized as gBlocks from IDT
(Supplementary Table S3). These gBlocks were used either directly as
positive controls in ESR1 mutation assay or cloned into a pCR2.1-TOPO TA
vector by Topo TA cloning kit (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s protocol. The gene fragment constructs were verified
by Sanger sequencing (Genewiz, New Jersey, USA). Locked Nucleic Acids
(LNA)-modified DNA oligonucleotide probes were synthesized by IDT
(Integrated DNA Technology, San Jose, CA, see Supplementary Table S3).
All LNA probes were 5′ end-labeled with either TET or FAM.
Patient sample collection and clinical data abstraction
All patients included in this study provided written informed consent to an
IRB-approved prospective biomarker study at the University of North
Carolina at Chapel Hill Cancer Hospital. The key inclusion criteria were
histologically confirmed ER+ breast cancer, stage IV disease, and a history
of progression on a prior line of endocrine therapy. Patients who
developed stage IV disease while on adjuvant endocrine therapy were
eligible for this study. De-identified blood samples were collected in the
clinical phlebotomy laboratory in coordination with clinician-ordered
laboratory tests. Follow-up blood collections were optional and based in
part on the following: circulating tumor DNA mutations were identified in
the initial blood sample by the lab; coordinator and phlebotomist
availability; and patient willingness and ability to provide an additional
blood sample. Assay results were not shared with clinical providers. We
performed clinical data abstraction using our institutional Electronic
Medical Record. PFS was measured from the time of the first blood
collection. For the serial timepoint analyses, the first blood sample was
collected at the start of a new systemic therapy, and subsequent blood
samples were collected at ~4–6 week intervals. Progression of disease was
determined by RECIST criteria on cross-sectional imaging or by clinician-
based confirmation of symptomatic progression.
Ethics approval and consent to participate
All patients included in this study provided written informed consent to an
IRB-approved prospective biomarker study at the University of North
Carolina at Chapel Hill Cancer Hospital.
Processing of plasma and extraction of circulating DNA
Blood samples were collected in cell-free DNA BCT® blood collection tubes
(Streck 218962). Within 1–4 h after blood collection, plasma and cells were
separated by two centrifugation steps at 2000 ×g. The plasma was stored
in 15ml polypropylene tubes at −80 °C until further use. A QIAamp
circulating nucleic acid kit (Qiagen, Valencia, CA, USA; Catalog No. 55114)
was used to extract DNA from 2 to 5 ml of plasma according to the
manufacturer’s protocol. The amount of purified ctDNA was quantified
with a Qubit® fluorometer and PicoGreen quantification reagents (Invitro-
gen, Carlsbad, CA, USA).
Analysis of ESR1 mutations by dPCR
A multiplexed panel was developed to detect hotspot ESR1 mutations at
amino acids 537 and 538. The 5-plex assay panel included a TET-
conjugated probe that recognized the wild type allele and four FAM-
conjugated probes targeting the p.D538G, p.Y537C, p.Y537N, and p.Y537S
alleles (Supplementary Fig S2). The 50 µl pre-PCR assay mixture contained
25 µl of TaqMan® Genotyping Master Mix (Applied Biosystems®) and 2.0 μl
Droplet Stabilizer (RainDanceTM Technologies, Billerica, MA), along with
0.9 µM of forward (5′-ATCTGTACAGCATGAAGTGCAAGA-3′) and reverse
primers (5′-CTAGTGGGCGCATGTAGGC-3′), 0.25 µM of TET-labeled wild-
type ESR1 probe and 0.25 µM of three FAM-labeled probes (p.Y537C, p.
Y537N and p.Y537S), 0.50 µM of FAM-labeled p.D538G probe, and 5–50 ng
of ctDNA. Emulsified droplets containing the PCR reaction components
were generated by the RainDrop® Source chip (RainDanceTM Technolo-
gies), followed by PCR amplification (Bio-Rad). The PCR cycling parameters
were 10min at 95 °C, then 45 cycles of 95 °C for 15 s and 60 °C for 1 min. A
slow ramping speed (0.5 °C) was used during cooling from the denatura-
tion step to the annealing step and the denaturation step immediately
following extension. Removing ramping between denaturation to anneal-
ing step and using 58 °C extension gave better separation of mutant
populations during droplet reading. After PCR amplification, the emulsion
was transferred to the RainDrop® Sense instrument (RainDanceTM
Technologies) to measure the end-point fluorescence signal in each
droplet. The recorded fluorescence intensity (“height”) and duration
(“width”) through FAM and VIC centered emission filters were analyzed
with RainDrop Analyst Software II (RainDanceTM Technologies).
Custom ThunderBolts open source NGS cancer panel
ThunderBolts Open Source System (RaindanceTM Technologies, Billerica,
MA) (TBOS-NGS-CP) was used for target enrichment and NGS analyses. A
custom NGS panel was designed on the ThunderBolts open source option
(Raindance) consisting of primers for 136 amplicons with 96 bp mean
amplicon size. ThunderBolts open source cancer panel used Raindance’s
proprietary algorithm to design mixture of two sets of primers (each set
consisted of mixture of 68 forward and 68 reverse primers) for targeted
enrichment of ESR1 (complete CDS), TP53 (complete CDS), PIK3CA
(hotspots), PIK3R1 (hotspots) and POLE (exonuclease domain). The
complete primer sequences are given in Supplementary Appendix 1. Each
primer was synthesized as 25nmol DNA oligo by IDT (Integrated DNA
Technology, San Jose, CA). The final pool of primers contained 0.16 nmol of
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Fig. 2 ESR1, PIK3CA and TP53 ctDNA mutations in MBC patients. a Progression-free survival of patients with any mutation in ESR1, PIK3CA, or
TP53 relative to patients with none of these mutations detected by either dPCR-SEQ or dPCR. Two-tailed P values calculated using the logrank
test. b Dynamic changes in MAF for ESR1, PIK3CA, and TP53 in plasma ctDNA. c Stacked histogram plots of cumulative MAF for ESR1, PIK3CA,
and TP53 in seven patients demonstrate heterogeneous ctDNA mutation dynamics during systemic therapy
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Sample preparation for NGS
The 40 µl reaction mixture consisted of Genotypic master mix (1×), droplet
stabilizer (1×), 2 µl of ThunderBolts set 1 or set 2 primers, and 5.0 ng of
ctDNA; the mixtures were loaded on each well of a RainDrop® Source chip
for droplet generation using the Source instrument (RainDanceTM
Technologies). The droplet emulsions with the set 1 and set 2 primers
for each sample were subject to PCR amplification with the following
conditions: 94 °C for 2 min; 55 cycles of 94 °C for 30 s, 54 °C for 30 s, 68 °C
for 1 min, and finally one incubation at 68 °C for 10min. The temperature
ramp speed between each step was 1 °C/second. The post-amplification
droplets were disrupted by adding 50 µl of droplet destabilizer (Rain-
DanceTM Technologies) and vortexing for 30 s followed by centrifugation at
2000× g for 2 min. After removal of the oil phase, the amplified DNA was
further purified with SPRIselectTM beads in accordance with the
ThunderBolts Cancer Panel Manual (RainDanceTM Technologies). A limited
cycle secondary PCR was performed on the purified DNA to append
indexed Illumina adaptors. The 25 µl secondary PCR reaction consisted of
3.25 µl of 10× Platinum Taq Pol HiFi Buffer, 0.875 µl of 50mM MgSO4,
1.124 µl of dNTP (10 mM each), 2.5 µl of 4 M Betaine, 1.25 µl DMSO, 1.25 µl
5 µM Universal forward primer, 1.25 of 5 µM Index reverse primer, 0.5 µl
Platinum Taq Pol HiFi, and 13 µl of the first PCR template DNA. The same
PCR cycling conditions were used for 10 cycles of amplification. The
amplicons were purified with SPRIselectTM beads as per the ThunderBolts
Cancer Panel Manual (RainDanceTM Technologies). The quantity and
quality of the libraries were evaluated using the Bioanalyzer high-
sensitivity DNA chip (Agilent Technologies, Palo Alto, CA). The library
prepared for each patient sample with distinct barcodes was diluted to
2 nM in nuclease-free water. From this stock, eight samples were pooled in
equal volumes. The pooled library was quantified with Qubit® fluorometer
and PicoGreen quantification reagents (Invitrogen, Carlsbad, CA, USA) and
Bioanalyzer high-sensitivity DNA chip (Agilent Technologies, Palo Alto, CA)
before running on MiSeq instrument. DNA libraries prepared from eight
samples were pooled for each MiSeq run.
MiSeq sequencing and data analysis
Each pooled library was sequenced using custom sequencing primers (5′-
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTG-3′ and 5′-GTGACTG-
GAGTTCAGACGTGTGCTCTTCCGATCTGAC-3′) and the MiSeq Reagent Kit
v3 2 × 300 bp on a MiSeq Sequencer (Illumina, San Diego, CA) according to
the manufacturer’s instructions. Paired end sequencing with 125 cycles
was performed. The FASTQ files were processed to remove adaptors and
any low quality bases at the ends of the reads (fastq-mcf, ea-utils-read-
only-1.04.636, default parameters except k= 2). Whole genome align-
ments of the adaptor-trimmed reads were performed against the reference
genome [hg38] using Bowtie2 (bowtie2–2.2.4, default parameters except
--local -N 1 -p 5).
Two groups of aligned reads were then selected. One group had both
reads mapped to the same amplicon on the correct strands, had primer
sequence matching the amplicon they map to within 1 bp mismatch, and
were at least 60 bp in length. The other group had both reads mapped to
the correct strand, were at least 60 bp in length, and mapped to different
amplicons within 1 kb of each other with primer sequences matching the
amplicons to which they mapped within 1 bp mismatch. BAM files were
created containing each of these two categories of reads and in which the
5′- and 3′-primer sequences were soft-clipped and the alignment positions
were adjusted. The two soft-clipped BAM files were merged and sorted.
The resulting single BAM file was converted to mpileup file (samtools-1.19
mpileup with parameters -A -B -d 1000000 -Q 30 -q 20) and subjected to
variant calling using VarScan2 (VarScan.v2.3.5.jar mpileup2snp and
mpileup2indel, --min-coverage 100 --min-reads2 1 --min-avg-qual 30
--min-var-freq 0 --strand-filter 1 --p-value 0.01 --output-vcf 1). The variants
detected by VarScan2 were annotated by snpEff (default parameters). Post-
processing of the variants was performed to filter out variants that were
also observed in the normal genomic DNA control.
Statistical analyses
Linear regression and survival analyses were performed in Prism 7
(Graphpad) software. PFS was estimated using the Kaplan–Meier (KM)
method. Two-sided log-rank test was applied to compare PFS of different
subgroups. Associations between clinical parameters and ESR1 mutation
status were evaluated using a Fisher’s exact test (for categorical variables)
and a student’s t-test (for continuous variables).
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